These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

460 related items for PubMed ID: 20672994

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml.
    Nishijima T, Komatsu H, Teruya K, Tanuma J, Tsukada K, Gatanaga H, Kikuchi Y, Oka S.
    AIDS; 2013 Mar 13; 27(5):839-42. PubMed ID: 23719354
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response.
    Podzamczer D, King MS, Klein CE, Flexner C, Katlama C, Havlir DV, Letendre SL, Eron JJ, Brun SC, Bernstein B.
    HIV Clin Trials; 2007 Mar 13; 8(4):193-204. PubMed ID: 17720659
    [Abstract] [Full Text] [Related]

  • 26. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
    Gallant JE, Koenig E, Andrade-Villanueva J, Chetchotisakd P, DeJesus E, Antunes F, Arastéh K, Moyle G, Rizzardini G, Fehr J, Liu Y, Zhong L, Callebaut C, Szwarcberg J, Rhee MS, Cheng AK.
    J Infect Dis; 2013 Jul 13; 208(1):32-9. PubMed ID: 23532097
    [Abstract] [Full Text] [Related]

  • 27. Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients.
    Murphy RL, da Silva BA, Hicks CB, Eron JJ, Gulick RM, Thompson MA, McMillan F, King MS, Hanna GJ, Brun SC.
    HIV Clin Trials; 2008 Jul 13; 9(1):1-10. PubMed ID: 18215977
    [Abstract] [Full Text] [Related]

  • 28. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.
    Hicks C, King MS, Gulick RM, White AC, Eron JJ, Kessler HA, Benson C, King KR, Murphy RL, Brun SC.
    AIDS; 2004 Mar 26; 18(5):775-9. PubMed ID: 15075512
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.
    Moyle GJ, Hardy H, Farajallah A, DeGrosky M, McGrath D.
    Clin Drug Investig; 2014 Apr 26; 34(4):287-96. PubMed ID: 24557728
    [Abstract] [Full Text] [Related]

  • 31. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
    Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES, AIDS Clinical Trials Group Study A5202 Team.
    N Engl J Med; 2009 Dec 03; 361(23):2230-40. PubMed ID: 19952143
    [Abstract] [Full Text] [Related]

  • 32. An open-label pilot study to determine the efficacy of lopinavir/ritonavir and tenofovir DF in the treatment of HIV-infected patients experiencing first virologic failure on a non-nucleoside-based regimen.
    Pierone G, Mieras J, Bulgin-Coleman D, Kantor C, Shearer J, Fontaine L, Fath M.
    AIDS Patient Care STDS; 2008 Apr 03; 22(4):263-6. PubMed ID: 18422459
    [No Abstract] [Full Text] [Related]

  • 33. A 48-week study of fat molecular alterations in HIV naive patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz.
    Domingo P, Gutierrez Mdel M, Gallego-Escuredo JM, Torres F, Mateo MG, Villarroya J, Lamarca K, Domingo JC, Vidal F, Villarroya F, Giralt M.
    J Acquir Immune Defic Syndr; 2014 Aug 15; 66(5):457-65. PubMed ID: 24820106
    [Abstract] [Full Text] [Related]

  • 34. Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT).
    Arasteh K, Weitner L, Fenske S, Kuhlmann B, Freiwald M, Ebrahimi R, Gallo L, Ranneberg R, Mertenskoetter T.
    Eur J Med Res; 2009 May 14; 14(5):195-9. PubMed ID: 19541575
    [Abstract] [Full Text] [Related]

  • 35. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
    Soriano V, Arastéh K, Migrone H, Lutz T, Opravil M, Andrade-Villanueva J, Antunes F, Di Perri G, Podzamczer D, Taylor S, Domingo P, Gellermann H, de Rossi L, ARTEN investigators.
    Antivir Ther; 2011 May 14; 16(3):339-48. PubMed ID: 21555816
    [Abstract] [Full Text] [Related]

  • 36. Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE).
    Shaffer D, Hughes MD, Sawe F, Bao Y, Moses A, Hogg E, Lockman S, Currier J.
    J Acquir Immune Defic Syndr; 2014 Jun 01; 66(2):155-63. PubMed ID: 24562349
    [Abstract] [Full Text] [Related]

  • 37. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R, Calza L.
    AIDS Patient Care STDS; 2008 Apr 01; 22(4):279-90. PubMed ID: 18290748
    [Abstract] [Full Text] [Related]

  • 38. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.
    Nelson MR, Elion RA, Cohen CJ, Mills A, Hodder SL, Segal-Maurer S, Bloch M, Garner W, Guyer B, Williams S, Chuck S, Vanveggel S, Deckx H, Stevens M.
    HIV Clin Trials; 2013 Apr 01; 14(3):81-91. PubMed ID: 23835510
    [Abstract] [Full Text] [Related]

  • 39. Sustained Viral Suppression in HIV-infected Children on Once-daily Lopinavir/Ritonavir in Clinical Practice.
    Gondrie IPE, Bastiaans DET, Fraaij PLA, Driessen GJA, van der Knaap LC, Visser EG, van Jaarsveld P, de Groot R, Hartwig NG, Burger DM, van Rossum AMC.
    Pediatr Infect Dis J; 2017 Oct 01; 36(10):976-980. PubMed ID: 28475554
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.